Arcutis Biotherapeutics, Inc. (ARQT) – SEC staff letter
2025-12-02 · Re: Form 10-K for the Fiscal Year Ended December 31, 2024 Filed February 25, 2025 · Accession 0000000000-25-011158 · Review completed (no further comments)
December 2, 2025 Latha Vairavan Chief Financial Officer Arcutis Biotherapeutics, Inc. 3027 Townsgate Road Suite 300 Westlake Village, California 91361 Re: Arcutis Biotherapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed February 25, 2025 File No. 001-39186 Dear Latha Vairavan: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of…
Full letter on EDGAR → · Filing index · All Arcutis Biotherapeutics, Inc. (ARQT) correspondence
Templates & resources
- AICPA & CIMA – SEC reporting resources (AICPA & CIMA · Professional body · Free / member)
- BDO Accounting, Reporting & Compliance Hub (ARCH) (BDO · Firm guide · Free)
- Deloitte DART – Roadmap Series (Deloitte · Firm guide · Free)
- Deloitte Roadmap: SEC Comment Letter Considerations (Deloitte · Firm guide · Free)
- KPMG Financial Reporting View (KPMG · Firm guide · Free)
- PwC Viewpoint (PwC · Firm guide · Free / paid)
- RSM Financial Reporting Resource Center (RSM · Firm guide · Free)
- SEC – EDGAR Full Text Search (SEC · Regulator · Free)